A detailed history of Principal Financial Group Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 84,796 shares of ACAD stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,796
Previous 96,214 11.87%
Holding current value
$1.38 Million
Previous $3.01 Million 47.97%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$17.79 - $30.86 $203,126 - $352,359
-11,418 Reduced 11.87%
84,796 $1.57 Million
Q4 2023

Feb 07, 2024

BUY
$20.78 - $31.77 $375,577 - $574,210
18,074 Added 23.13%
96,214 $3.01 Million
Q3 2023

Nov 02, 2023

BUY
$20.84 - $33.47 $311,724 - $500,644
14,958 Added 23.67%
78,140 $1.63 Million
Q2 2023

Aug 07, 2023

SELL
$17.8 - $25.65 $63,207 - $91,083
-3,551 Reduced 5.32%
63,182 $1.51 Million
Q1 2023

May 09, 2023

SELL
$16.32 - $20.92 $134,476 - $172,380
-8,240 Reduced 10.99%
66,733 $1.26 Million
Q4 2022

Feb 09, 2023

BUY
$14.2 - $18.63 $126,025 - $165,341
8,875 Added 13.43%
74,973 $1.19 Million
Q3 2022

Nov 09, 2022

SELL
$14.11 - $18.27 $738,023 - $955,612
-52,305 Reduced 44.18%
66,098 $1.08 Million
Q2 2022

Aug 10, 2022

BUY
$13.01 - $27.22 $1.02 Million - $2.12 Million
78,054 Added 193.45%
118,403 $1.67 Million
Q1 2022

May 09, 2022

BUY
$20.94 - $27.5 $18,510 - $24,310
884 Added 2.24%
40,349 $977,000
Q4 2021

Feb 09, 2022

SELL
$16.79 - $27.09 $308,566 - $497,860
-18,378 Reduced 31.77%
39,465 $921,000
Q3 2021

Nov 09, 2021

BUY
$15.78 - $24.77 $27,757 - $43,570
1,759 Added 3.14%
57,843 $961,000
Q2 2021

Aug 10, 2021

BUY
$19.4 - $27.42 $153,124 - $216,426
7,893 Added 16.38%
56,084 $0
Q1 2021

May 10, 2021

BUY
$25.02 - $54.99 $52,817 - $116,083
2,111 Added 4.58%
48,191 $1.24 Million
Q4 2020

Feb 08, 2021

SELL
$41.04 - $56.79 $26,511 - $36,686
-646 Reduced 1.38%
46,080 $2.46 Million
Q3 2020

Nov 06, 2020

SELL
$36.42 - $57.0 $359,064 - $561,963
-9,859 Reduced 17.42%
46,726 $0
Q2 2020

Aug 05, 2020

SELL
$39.26 - $52.73 $357,226 - $479,790
-9,099 Reduced 13.85%
56,585 $2.74 Million
Q1 2020

May 12, 2020

BUY
$31.65 - $46.87 $74,852 - $110,847
2,365 Added 3.74%
65,684 $2.78 Million
Q4 2019

Feb 05, 2020

SELL
$36.21 - $51.4 $1.11 Million - $1.58 Million
-30,646 Reduced 32.61%
63,319 $2.71 Million
Q3 2019

Nov 13, 2019

BUY
$22.22 - $44.01 $186,159 - $368,715
8,378 Added 9.79%
93,965 $3.38 Million
Q2 2019

Aug 12, 2019

BUY
$23.32 - $28.12 $1.23 Million - $1.49 Million
52,869 Added 161.59%
85,587 $2.29 Million
Q1 2019

May 10, 2019

BUY
$16.17 - $27.38 $26,955 - $45,642
1,667 Added 5.37%
32,718 $879,000
Q4 2018

Feb 14, 2019

SELL
$14.32 - $22.92 $100,282 - $160,508
-7,003 Reduced 18.4%
31,051 $502,000
Q3 2018

Nov 14, 2018

BUY
$13.03 - $21.81 $65,892 - $110,293
5,057 Added 15.33%
38,054 $790,000
Q2 2018

Aug 13, 2018

SELL
$15.07 - $22.34 $23,931 - $35,475
-1,588 Reduced 4.59%
32,997 $0
Q1 2018

May 14, 2018

BUY
$22.47 - $32.33 $38,918 - $55,995
1,732 Added 5.27%
34,585 $777,000
Q4 2017

Feb 13, 2018

BUY
$26.84 - $39.14 $524,024 - $764,169
19,524 Added 146.48%
32,853 $989,000
Q3 2017

Nov 02, 2017

BUY
$29.49 - $38.37 $393,072 - $511,433
13,329
13,329 $502,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.63B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.